NR3C2 and kidney disorder: In large clinical trials, sodium-glucose cotransporter 2 inhibitors (SGLT2is) and a mineralocorticoid receptor antagonist—finerenone—were shown to reduce proteinuria and ultimately slow kidney disease progression to end-stage kidney disease [21,22,23,24].